- €26.24m
- €18.95m
- €4.47m
Brief: Nanorepro Wins Order To Deliver Rapid Coronavirus Tests
Brief: Nanorepro FY Turnover Up At EUR 16.9 Million
Brief: Nanorepro Says Capital Increase Significantly Oversubscribed
Brief: Nanorepro Says First Major Order For Corona Antigen Test
Brief: NanoRepro Carries Out Capital Increase To Prefinance Larger Orders
Brief: NanoRepro Announces More Details On Capital Increase
Brief: Nanorepro Resolves Cash Capital Increase By Up To EUR 2,640,000.00
Brief: NanoRepro Receives Order For 1 Mln Coronavirus-Antigen Tests
Brief: Nanorepro Receives Antigen Test Orders For EUR 2.5 Million
Brief: Nanorepro Confirms Forecast Of Ending H2 2020 Better H1
Brief: Nanorepro Starts Selling New Antigen Test For Detection Of Coronavirus
Brief: Nanorepro H1 Sales Up 179% To 2.2 Million Euros
Brief: Nanorepro Says CFO Michael Fuchs Leaves
Brief: NanoRepro Sees To Post Profit in H1
Brief: Nanorepro Starts Delivering COVID-19 Test
Brief: Nanorepro FY EBITDA At EUR -0.8 Mln
Brief: Nanorepro Places 10% Capital Increase
Brief: Nanorepro Now Sees Significant Decline In Sales For 2019
Brief: Nanorepro Q1 EBITDA Swings To Loss Of EUR 293,400